Hybrid Modeling
Method notes, results and company news from Novasign.
BioprocessBioprocess DevelopmentMar 20, 2026De‑Risking Bioprocess Scale‑Up: Predictive Modeling for Reliable Fermentation and Cell Culture Manufacturing
Scaling a bioprocess from laboratory development to industrial manufacturing is one of the most critical, and risky steps in biotechnology. For contract development and manufacturing organizations (CDMOs), large pharmaceutical companies, industrial biotechnology producers, and emerging sectors such…
BioprocessBioprocess DevelopmentMar 20, 2026Autonomous Continuous Biomanufacturing: Closing the Gap Between Process Development and Production
Continuous biomanufacturing has long been considered one of the most promising approaches to increase productivity, reduce facility footprint, and enable more sustainable bioprocessing.
BioprocessBioprocess DevelopmentMar 20, 2026Next‑Generation Media Development: How Modeling Reduces Cost and Accelerates Bioprocess Optimization
Media composition is one of the least transparent elements in modern cell culture bioprocess development. Whether producing monoclonal antibodies, recombinant proteins, industrial enzymes, or cultivated food products, the composition of the cell culture or fermentation media directly determines…
BioprocessBioprocess DevelopmentApr 3, 2025Hybrid Modeling Meets Filtration: Optimizing UF and DF in Monoclonal Antibody Processing
Producing monoclonal antibodies often involves the challenge of balancing high protein concentrations with the risk of membrane fouling or poor recovery. Our innovative workflow captures detailed experimental data from a single experiment to characterize key variables like membrane behavior and…
- Bioprocess DevelopmentDigital TwinDec 3, 2024
Viral Vector Manufacturing: 64% Fewer Experiments in Lytic Virus Production
In a recent project with our strategic partner bespark*bio, we combined our hybrid modeling with best-in-class bioprocessing expertise to maximize the efficiency of a Vero cell culture process producing a lytic virus. This approach to process optimization showed that instead of requiring 22…
- Bioprocess DevelopmentBiotechnologyJul 28, 2021
Antleron and Novasign to join forces in ATMP Modeling
Advanced therapy medicinal products (ATMPs) are targeted therapies based on genes, cells, or tissues that deliver a therapeutic benefit to a patient-specific population and often treat rare diseases or improve upon existing treatments. The global ATMP market is expected to reach approximately 21.2…
BiotechnologyHybrid ModelingOct 15, 2020Novasign Soft Sensing Technology at Siemens’ LivingLab
Innovative tools to monitor important upstream bioprocess variables in real-time, such as biomass, are of high interest for manufacturers. Typically, to get these values, a sample must be drawn, processed, and analyzed. These steps lead to an inevitable time delay, which makes this desired…
Bioprocess DevelopmentBiotechnologyOct 18, 2019The Hybrid Modeling Summer School 2019
From the 25th to the 27th of September, Novasign co-hosted the 4th hybrid modeling summer school in Lisbon, Portugal. After a very detailed introduction to hybrid modeling by Prof. Rui Oliveira and Moritz von Stosch, the 41 participants were introduced to the pre-release Novasign hybrid modeling…
BiotechnologyHybrid ModelingMar 27, 2019Bioprocessing Europe Lisbon
Last week we have been to Bioprocessing Europe in Lisbon. The conference was organized in a brought manner, offering both, an up- and downstream processing stream, as well as a gene and cell therapy stream. With more than 100 experts presenting their current bleeding and cutting edge technology,…
9 of 9 posts